Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Effect of Supplemental Oxygen on Maximal Oxygen Consumption in Patients With Chronic Obstructive Pulmonary Disease
Effect of Therapeutic Hyperoxia on Maximal Oxygen Consumption and Perioperative Risk Stratification in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  3/15/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Effect of Supplemental Oxygen on Maximal Oxygen Consumption in Patients With Chronic Obstructive Pulmonary Disease
Effect of Therapeutic Hyperoxia on Maximal Oxygen Consumption and Perioperative Risk Stratification in Patients With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 3/15/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Comparing Fitbit® Quality of Measured Sleep to Sleep Measured by Polysomnography in the Sleep Lab
Comparing Fitbit® Quality of Measured Sleep to Sleep Measured by Polysomnography in the Sleep Lab
Status: Enrolling
Updated:  3/15/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Comparing Fitbit® Quality of Measured Sleep to Sleep Measured by Polysomnography in the Sleep Lab
Comparing Fitbit® Quality of Measured Sleep to Sleep Measured by Polysomnography in the Sleep Lab
Status: Enrolling
Updated: 3/15/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Transplant Optimization Using Functional Imaging
Transplant Optimization Using Functional Imaging
Status: Enrolling
Updated:  3/28/2017
Columbia University Medical Center
mi
from
New York, NY
Transplant Optimization Using Functional Imaging
Transplant Optimization Using Functional Imaging
Status: Enrolling
Updated: 3/28/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Transplant Optimization Using Functional Imaging
Transplant Optimization Using Functional Imaging
Status: Enrolling
Updated:  3/28/2017
Hospital of the University of Pennsylvania
mi
from
Gibson, PA
Transplant Optimization Using Functional Imaging
Transplant Optimization Using Functional Imaging
Status: Enrolling
Updated: 3/28/2017
Hospital of the University of Pennsylvania
mi
from
Gibson, PA
Click here to add this to my saved trials
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease
Status: Enrolling
Updated:  4/3/2017
Riley Hospital for Children at Indiana University Health
mi
from
Indianapolis, IN
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease
Status: Enrolling
Updated: 4/3/2017
Riley Hospital for Children at Indiana University Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease
Status: Enrolling
Updated:  4/3/2017
St. Louis Children's Hospital
mi
from
St. Louis, MO
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease
Status: Enrolling
Updated: 4/3/2017
St. Louis Children's Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease
Status: Enrolling
Updated:  4/3/2017
The Royal Children's Hospital
mi
from
Melbourne,
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease
Status: Enrolling
Updated: 4/3/2017
The Royal Children's Hospital
mi
from
Melbourne,
Click here to add this to my saved trials
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated:  4/4/2017
University of Colorado DHSC
mi
from
Boulder, CO
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated: 4/4/2017
University of Colorado DHSC
mi
from
Boulder, CO
Click here to add this to my saved trials
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated:  4/4/2017
Mercy Hospital St. Louis
mi
from
St. Louis, MO
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated: 4/4/2017
Mercy Hospital St. Louis
mi
from
St. Louis, MO
Click here to add this to my saved trials
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated:  4/4/2017
Washington University School of Medicine in St. Louis
mi
from
St. Louis, MO
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated: 4/4/2017
Washington University School of Medicine in St. Louis
mi
from
St. Louis, MO
Click here to add this to my saved trials
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated:  4/4/2017
Cleveland Clinic Lerner College of Medicine
mi
from
Cleveland, OH
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated: 4/4/2017
Cleveland Clinic Lerner College of Medicine
mi
from
Cleveland, OH
Click here to add this to my saved trials
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated:  4/4/2017
The Ohio State Univsersity Medical Center
mi
from
Columbus, OH
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated: 4/4/2017
The Ohio State Univsersity Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated:  4/4/2017
Oregon Health and Science University
mi
from
Portland, OR
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated: 4/4/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated:  4/4/2017
University of Texas Health Science Center
mi
from
Houston, TX
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated: 4/4/2017
University of Texas Health Science Center
mi
from
Houston, TX
Click here to add this to my saved trials
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated:  4/4/2017
Erasme University Hospital
mi
from
Brussels,
Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)
A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)
Status: Enrolling
Updated: 4/4/2017
Erasme University Hospital
mi
from
Brussels,
Click here to add this to my saved trials
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Status: Enrolling
Updated:  4/4/2017
Iowa City VA Health Care System
mi
from
Iowa City, IA
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Status: Enrolling
Updated: 4/4/2017
Iowa City VA Health Care System
mi
from
Iowa City, IA
Click here to add this to my saved trials
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Status: Enrolling
Updated:  4/4/2017
University of Iowa
mi
from
Iowa City, IA
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Combined Illness Management and Psychotherapy in Treating Depressed Elders
Status: Enrolling
Updated: 4/4/2017
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Aripiprazole to Reduce Cocaine Relapse
Preventing Cocaine Relapse: Developing Pharmacotherapies
Status: Enrolling
Updated:  4/5/2017
University of Kentucky
mi
from
Lexington, KY
Aripiprazole to Reduce Cocaine Relapse
Preventing Cocaine Relapse: Developing Pharmacotherapies
Status: Enrolling
Updated: 4/5/2017
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Evaluation of the Versamed iVent in the Transport of Patients Receiving Mechanical Ventilation
Evaluation of the Versamed iVent in the Transport of Patients Receiving Mechanical Ventilation
Status: Enrolling
Updated:  4/5/2017
Tufts Medical Center
mi
from
Boston, MA
Evaluation of the Versamed iVent in the Transport of Patients Receiving Mechanical Ventilation
Evaluation of the Versamed iVent in the Transport of Patients Receiving Mechanical Ventilation
Status: Enrolling
Updated: 4/5/2017
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Advances In Medicine
mi
from
Rancho Mirage, CA
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Advances In Medicine
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Delaware Medical Care Associates, LLC
mi
from
Newark, DE
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Delaware Medical Care Associates, LLC
mi
from
Newark, DE
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
LaPorte County Institute for Clinical Research Inc.
mi
from
Michigan City, IN
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
LaPorte County Institute for Clinical Research Inc.
mi
from
Michigan City, IN
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
University of Kentucky
mi
from
Lexington, KY
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
University of Toledo College of Medicine
mi
from
Toledo, OH
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
University of Toledo College of Medicine
mi
from
Toledo, OH
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
UCLA Division of Rheumatology
mi
from
Los Angeles, CA
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
UCLA Division of Rheumatology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Georgetown University School of Medicine
mi
from
Washington,
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Georgetown University School of Medicine
mi
from
Washington,
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
USF Health Faculty Office Building-FOB
mi
from
Tampa, FL
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
USF Health Faculty Office Building-FOB
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Arthritis Research and Treatment Center
mi
from
Stockbridge, GA
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Arthritis Research and Treatment Center
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Louisiana State Univ.
mi
from
Shreveport, LA
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Louisiana State Univ.
mi
from
Shreveport, LA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Boston University of Medicine BUMC
mi
from
Boston, MA
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Boston University of Medicine BUMC
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
University of Michigan
mi
from
Ann Arbor, MI
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
UMDNJ-Robert Wood Johnson Medical School Clinical Research Center
mi
from
New Brunswick, NJ
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
UMDNJ-Robert Wood Johnson Medical School Clinical Research Center
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
North Shore-LIJ Health System-Division of Rheumatology
mi
from
Great Neck, NY
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
North Shore-LIJ Health System-Division of Rheumatology
mi
from
Great Neck, NY
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Cleveland Clinic
mi
from
Cleveland, OH
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated:  4/5/2017
Monash Medical Centre
mi
from
Clayton,
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease
Status: Enrolling
Updated: 4/5/2017
Monash Medical Centre
mi
from
Clayton,
Click here to add this to my saved trials
Need for the Assessment and Consultation Team (ACT) Following Anesthetic Care
Etiology of Post-anesthetic and Post-sedation Events on the Inpatient Ward: Data From a Rapid Response Team at a Tertiary Care Children's Hospital
Status: Enrolling
Updated:  4/5/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Need for the Assessment and Consultation Team (ACT) Following Anesthetic Care
Etiology of Post-anesthetic and Post-sedation Events on the Inpatient Ward: Data From a Rapid Response Team at a Tertiary Care Children's Hospital
Status: Enrolling
Updated: 4/5/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Carbamazepine Treatment of Cocaine Dependence - 1
Carbamazepine Treatment of Cocaine Dependence
Status: Enrolling
Updated:  4/6/2017
Medical University of South Carolina
mi
from
Charleston, SC
Carbamazepine Treatment of Cocaine Dependence - 1
Carbamazepine Treatment of Cocaine Dependence
Status: Enrolling
Updated: 4/6/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Vitamin D and Microbiota in Cystic Fibrosis
Pilot Study Evaluating the Role of Vitamin D Repletion on Gut and Lung Microbiota in Cystic Fibrosis
Status: Enrolling
Updated:  4/12/2017
The Emory Clinic
mi
from
Atlanta, GA
Vitamin D and Microbiota in Cystic Fibrosis
Pilot Study Evaluating the Role of Vitamin D Repletion on Gut and Lung Microbiota in Cystic Fibrosis
Status: Enrolling
Updated: 4/12/2017
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
Biomarkers for Obstructive Sleep Apnea
Towards a Blood Test for Diagnosis of Obstructive Sleep Apnea
Status: Enrolling
Updated:  4/17/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Biomarkers for Obstructive Sleep Apnea
Towards a Blood Test for Diagnosis of Obstructive Sleep Apnea
Status: Enrolling
Updated: 4/17/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects
A Single Centre, Three Part, Randomised, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Subjects
Status: Enrolling
Updated:  4/25/2017
GSK Investigational Site
mi
from
Baltimore, MD
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects
A Single Centre, Three Part, Randomised, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Subjects
Status: Enrolling
Updated: 4/25/2017
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)
Status: Enrolling
Updated:  4/25/2017
Brown University, Lifespan
mi
from
Providence, RI
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)
Status: Enrolling
Updated: 4/25/2017
Brown University, Lifespan
mi
from
Providence, RI
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Rancho Mirage, CA
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Colorado Springs, CO
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Waterbury, CT
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Waterbury, CT
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Clearwater, FL
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Clearwater, FL
Click here to add this to my saved trials